17th Annual LD Micro Main Event Conference
Logotype for Cibus Inc

Cibus (CBUS) 17th Annual LD Micro Main Event Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Cibus Inc

17th Annual LD Micro Main Event Conference summary

3 Feb, 2026

Technology and innovation

  • Focus on gene editing to develop crop traits that are indistinguishable from natural or traditional breeding, enabling rapid introduction of new characteristics in major crops.

  • Rapid Trait Development System (RTDS) accelerates trait development from centuries to weeks or months, using precise DNA edits without introducing foreign DNA.

  • Traits target productivity, weed control, disease resistance, and yield protection, with ongoing development for canola, rice, and soybean.

  • Technology enables stacking and updating of traits, similar to software updates, with low incremental costs per new variety.

  • Regulatory changes globally, including in Europe, now differentiate gene-edited crops from GMOs, opening new markets and facilitating trade.

Business model and partnerships

  • Operates a trait licensing and royalty business, partnering with major seed companies and non-seed partners for sustainable ingredients.

  • Five-trait pipeline focused on canola, rice, and soybean, with traits for weed management, disease resistance, and pod shatter reduction.

  • No exclusive licensing; traits are licensed to multiple customers, with field trials demonstrating effectiveness before customer adoption.

  • Royalty revenue is expected to begin in 2026, with a stable and growing addressable market, especially in soybeans.

  • Estimated trait value per acre ranges from $5 to $15, with rice traits offering higher annual royalty potential.

Financial outlook and funding

  • Currently pre-revenue, with reported income from R&D funding rather than trait royalties.

  • Annual cash burn is under $50 million, with financing needs until royalty revenue starts in 2026.

  • Plans to bridge funding gap through equity raises and potentially royalty debt.

  • Cost to upgrade or add new traits is significantly lower than traditional GMO development, often less than $100,000 per variety.

  • Long-term royalty streams are expected to be highly recurring and sticky, similar to historical GMO trait royalties.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more